VANCOUVER, British Columbia–(BUSINESS WIRE)–SaNOtize Research and Development Corp. (“SaNOtize”), a Canadian anti-infective-focused therapeutics company, today announced that the company has appointed Steven Basta, an experienced biopharma and medical device commercial leader, as its new Chief Executive Officer (CEO). Co-Founder Gilly Regev, PhD, will transition from her role as CEO to Chief Strategy and Innovation Officer at SaNOtize and will remain a member of its Board of Directors.
For more than 20 years, Basta has led publicly and privately held companies, demonstrating a strong track record of product development, commercialization, partnering, and private and public financings of these companies.
“I am honored to be appointed CEO of SaNOtize, a company that has done groundbreaking work in nitric oxide therapeutics,” said Basta. “In many indications, there is a significant need for effective and accessible antimicrobial solutions. SaNOtize has led the charge with its antiviral nasal spray, approved in certain markets for Covid-19 treatment, and is well positioned to advance and commercialize its suite of nitric-oxide-based therapeutics to treat common viral, bacterial, and fungal infections.”
Basta’s appointment comes on the heels of Dr. Regev’s decision to step down as CEO after almost seven years at the helm. “I believe SaNOtize is ready for its next phase of leadership,” said Dr. Regev. “In the search for my successor, we aimed to find someone with a passion for bringing lifesaving therapies to market – and we certainly found this in Steve. With more than three decades of strategic and operational experience in therapeutics and medical technology, Steve was a natural choice. His experience, exuberance, and drive will undoubtedly make him a fierce advocate and leader of the SaNOtize family.”
“We are so excited to welcome Steve to the company and thrilled Gilly will continue to be involved in its future,” said SaNOtize Chairperson Elaine Campbell. “SaNOtize has great things in store and remains committed to our mission to bring safe and effective antimicrobial therapeutics to people around the world.”
Prior to joining SaNOtize, Basta led several development stage and commercial therapeutics and medical device companies including Mahana Therapeutics, Menlo Therapeutics, AlterG, Merz Aesthetics, and BioForm Medical. Basta holds an MBA from Kellogg Graduate School of Management and a BA in Biomedical Engineering from The Johns Hopkins University.
SaNOtize Research & Development Corp. is a pharmaceutical company based in Vancouver, BC, commercializing the multi-faceted antimicrobial properties of a liquid producing nitric oxide. The company has developed and patented a Nitric Oxide Releasing Solution platform technology (NORS™) to treat and prevent upper respiratory and topical infections. For more information, visit www.SaNOtize.com. Follow us on social: LinkedIn and Twitter.